CERTAIN IDENTIFIED CONFIDENTIAL INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT BECAUSE IT IS (I) CUSTOMARILY AND ACTUALLY TREATED AS PRIVATE OR CONFIDENTIAL AND (II) NOT MATERIAL. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. Revenue...Purchase and Sale Agreement • February 12th, 2025 • Ascendis Pharma a/S • Pharmaceutical preparations • New York
This REVENUE PARTICIPATION RIGHT purchase and sale AGREEMENT (this “Agreement”), dated as of September 3, 2024 (the “Effective Date”), is made and entered into by and between Royalty Pharma Development Funding, LLC, a Delaware limited liability company (the “Buyer”), Ascendis Pharma Bone Diseases A/S, a corporation organized under the laws of Denmark (the “Seller”) and Ascendis Pharma A/S, a public limited liability company (Aktieselskab) organized under the laws of Denmark (the “Parent” of the Seller).
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS SUCH OMITTED INFORMATION AS PRIVATE OR CONFIDENTIAL, AND SUCH INFORMATION IS NOT MATERIAL. Revenue...Purchase and Sale Agreement • February 7th, 2024 • Ascendis Pharma a/S • Pharmaceutical preparations • New York
This REVENUE PARTICIPATION RIGHT purchase and sale AGREEMENT (this “Agreement”), dated as of September 5, 2023 (the “Effective Date”), is made and entered into by and between Royalty Pharma Development Funding, LLC, a Delaware limited liability company (the “Buyer”), Ascendis Pharma Endocrinology Division A/S, a corporation organized under the laws of Denmark (the “Seller”) and Ascendis Pharma A/S, a public limited liability company (Aktieselskab) organized under the laws of Denmark (the “Parent” of the Seller).